Product Images Gabapentin

The figure shows the mean pain score over a period of eight weeks, with a four-week dose titration period followed by a four-week fixed dose period. The medication being studied is Gabapentin, with a maximum dose of 3600 mg/day, and a placebo is also included for comparison. The mean pain score decreases over time for both the Gabapentin and placebo groups. Statistics indicate a significant difference between the two groups with p<0.01.*

The text describes a pain study with a 3-week dose titration period and a 4-week fixed dose period, in which three treatment groups (placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day) were evaluated for their weekly mean pain scores. The graph shows the observed cases in the ITT population across seven weeks, with p<0.01.*

The text describes the results of two controlled studies examining the percentage of responders (patients with >50% reduction in pain score) at endpoint in the treatment of post-herpetic neuralgia (PHN) using two drugs - PBO and GBP. The proportion of responders is presented graphically in Figure 3, and asterisks are used to denote statistical significance. However, without further context or details, it is not possible to understand the full implications of these results.*